Clinical Trial

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases

Name: Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases — clinical trial record (NCT07490041)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Cell therapy

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA CAR-NK cell injection in patients with refractory pediatric rheumatic diseases.

Trial Details

NCT Number	NCT07490041
Lead Sponsor	The Children's Hospital of Zhejiang University School of Medicine Collaborators: Rui Therapeutics Co., Ltd
Conditions	Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese), Systemic Lupus Erythematosus (SLE), Connective Tissue Disease-associated Interstitial Lung Disease
Enrollment	36 participants
Start Date	2026-03-19
Primary Completion	2026-12-19 (estimated)
Study Completion	2027-12-19 (estimated)
Updated on ClinicalTrials.gov	2026-03-24